cT1 N0 M0 非小细胞肺癌肺段切除术后长期预后
本研究基于一项前瞻性队列的回顾性分析,纳入 2005 至 2009 年接受肺段切除的 179 例周围型 cT1 N0 M0 非小细胞肺癌患者,中位随访 108 个月。各临床分期 10 年无复发生存率分别为 Tis 100%、T1mi 或 T1a 97%、T1b 90%、T1c 69%,分期越晚越低(p < 0.001)。结论认为肺段切除可作为 T1 N0 M0 的根治选择,但术后 5 年以上仍需监测局部复发。
要点
- 各临床分期 10 年无复发生存率:Tis 100%、T1mi/T1a 97%、T1b 90%、T1c 69%,随 T 分期升高而降低。
- 8 例局部复发中 6 例发生在术后 5 年以上,均经局部治疗,6 例无病生存。
核心结论
- 肺段切除可能是 T1 N0 M0 非小细胞肺癌的可行根治选择,但术后 5 年以上仍需继续监测局部复发,以免错过根治机会。
研究设计与样本
- 本研究为对既往前瞻性队列研究的回顾性分析,纳入 2005 至 2009 年接受肺段切除的周围型 cT1 N0 M0 非小细胞肺癌患者,中位随访 108 个月。
- 排除标准包括右中叶肿瘤、同一肺叶多发肿瘤、肺段切除风险较大及要求行肺叶切除而非肺段切除的患者。
- 研究结局包括总生存、无复发生存概率和局部复发。
主要发现
- 179 例患者中临床 T 分期为 Tis 57 例、T1mi 或 T1a 34 例、T1b 57 例、T1c 31 例,所有肿瘤均为病理 N0。
- 各临床分期 10 年无复发生存概率为 Tis 100%、T1mi 或 T1a 97%、T1b 90%、T1c 69%,分期越晚越低(p < 0.001)。
- 8 例局部复发均接受局部治疗,追加治疗后中位随访 55 个月时 6 例无病生存。
临床怎么用
- 对 cT1 N0 M0 非小细胞肺癌行肺段切除后,随访应持续 5 年以上,重点关注切缘及保留肺叶的局部复发。
- T1c 患者 10 年无复发生存概率为 69%,属复发风险较高人群,宜加强术后监测。
局限性
- 本研究为单中心回顾性分析,样本量 179 例,且为对既往前瞻性队列的二次分析。
- 原文未报告总生存的具体数值,随访方案与监测间隔亦未说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognosis beyond 5 years after segmentectomy for non-small cell lung cancer (NSCLC) has not been well studied. METHODS: This study is a retrospective analysis of a previous prospective cohort study of patients with peripheral cT1 N0 M0 NSCLC who underwent segmentectomy between 2005 and 2009. Exclusion criteria were right middle lobe tumors, multiple tumors in same lobe, patients having considerable risk for segmentectomy, and patients requesting lobectomy rather than segmentectomy. The median follow-up period was 108 months. Study outcomes included overall survival, recurrence-free probability, and local recurrence. RESULTS: Of 179 patients with cT1 N0 M0 who were treated by segmentectomy, clinical T stages were Tis in 57 patients, T1mi or T1a in 34, T1b in 57, and T1c in 31. All tumors were pathologic N0 tumors. The 10-year recurrence-free probability rates in each clinical stage were 100% in Tis, 97% in T1mi or T1a, 90% in T1b, and 69% in T1c, which were significantly lower in advanced T stages (p < 0.001). Fourteen patients (8%) experienced recurrences after segmentectomy; these were local in 8 patients (five recurrences at the surgical margin and three in the preserved lobe) and nonlocal in 6 patients. Six of the eight local recurrences developed more than 5 years after segmentectomy. All eight local recurrences were treated by local therapy, resulting in 6 patients surviving without disease at 55 months of median follow-up after the additional treatments. CONCLUSIONS: Although segmentectomy may be a viable curative option for treating T1 N0 M0 NSCLC, monitoring for local recurrence should be continued beyond 5 years after segmentectomy to avoid missing opportunities to effect a cure.
引用
- Nomori H, Mori T, Shiraishi A, et al. Long-Term Prognosis After Segmentectomy for cT1 N0 M0 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018. PMID: 30579848. doi:10.1016/j.athoracsur.2018.11.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。